Elucid news and updates

Every material change AI Health Index has tracked at Elucid: new modules, model and architecture updates, clinical evidence, regulatory status, security certifications, and integration depth. Each entry states what changed, cites its source, and carries our read on what it means for a buyer. The graded assessment of this vendor across all fifteen capability axes sits on its index profile.

Funding rounds, valuations, and awards are not product changes and are not logged here. Acquisitions appear only where there is direct product impact.

Follow this change log by RSS

Free for your reader, newsletter or automation tool. One feed covers the whole index, and every category has its own.

All feeds and terms
Impact
Type
1 entry
Showing changes for Elucid only.Show the full log

November 2026

E
Elucid
Nov 3, 2026
MediumPartially Verified
Clinical evidence

Elucid presented ELUCIDATE results at TCT 2026, a multicenter retrospective validation of its FDA cleared FFR-IQ BioIntegrated FFR-CT software in 491 vessels from 347 patients at 11 U.S. and European sites, with invasive measurements reviewed by the Cardiovascular Research Foundation core lab. The study met both primary endpoints with 92.2 percent sensitivity, 93.1 percent specificity and 92.9 percent vessel level accuracy versus invasive FFR, and 84.1 percent accuracy (AUC 0.879) in the 0.75 to 0.85 gray zone. The cohort had no overlap with model development or internal testing data, and the model was locked before validation.

Our read

Cardiology and imaging buyers comparing FFR-CT options get core lab adjudicated accuracy figures, including gray zone performance near the 0.80 treatment threshold where FFR-CT results drive cath lab referral decisions.

Related axis: Clinical and Operational EvidenceVendor announcementView source

What has changed at Elucid recently?

The most recent change AI Health Index logged at Elucid is dated Nov 3, 2026. Elucid presented ELUCIDATE results at TCT 2026, a multicenter retrospective validation of its FDA cleared FFR-IQ BioIntegrated FFR-CT software in 491 vessels from 347 patients at 11 U.S. and European sites, with invasive measurements reviewed by the Cardiovascular Research Foundation core lab.